Ostatné · MRK
Merck & Company, Inc.
Fundamenty firmy Healthcare · Drug Manufacturers - General · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 25 hodnotení
nákup
- Najnižší cieľ
- 105,00
- Priemerný cieľ
- 155,76
- Najvyšší cieľ
- 186,00
- Potenciál
- +11,6 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 2,18 | 1,80–2,34 | 2,58 | −15,6 % |
| budúci štvrťrok | 1,96 | 1,82–2,25 | 2,04 | −4,0 % |
| tento rok | 2,73 | 2,58–2,83 | 8,98 | −69,6 % |
| budúci rok | 9,47 | 8,41–10,36 | 2,73 | +247,1 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 17,3 mld. | 17,3 mld. | +0,3 % |
| budúci štvrťrok | 16,8 mld. | 16,4 mld. | +2,7 % |
| tento rok | 67,1 mld. | 65,0 mld. | +3,3 % |
| budúci rok | 70,2 mld. | 67,1 mld. | +4,6 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Guindo ChirfiOfficer | predaj | 1,4 mil. | 13.08. |
| Deluca Richard Robert Jr.Officer | predaj | 5,9 mil. | 12.08. |
| Zachary Jennifer LGeneral Counsel | predaj | 10,7 mil. | 12.08. |
| Zachary Jennifer LGeneral Counsel | uplatnenie opcií | 6,0 mil. | 12.08. |
| Deluca Richard Robert Jr.Officer | predaj | 788 773 | 06.08. |
| Guindo ChirfiOfficer | predaj | 2,0 mil. | 06.08. |
| Maraldo David R.Officer | predaj | 2,4 mil. | 05.08. |
| Williams David MichaelChief Technology Officer | predaj | 6,8 mil. | 05.08. |
| Maraldo David R.Officer | uplatnenie opcií | 1,5 mil. | 05.08. |
| Williams David MichaelChief Technology Officer | uplatnenie opcií | 3,9 mil. | 05.08. |
| Maraldo David R.Officer | uplatnenie opcií | 61 912 | 01.05. |
| Smart Dalton E. IiiOfficer | uplatnenie opcií | 42 957 | 01.05. |
Kto vlastní akcie
Blackrock Inc.9,20 %
Vanguard Capital Management LLC6,54 %
State Street Corporation4,88 %
Wellington Management Group, LLP3,50 %
Vanguard Portfolio Management LLC2,75 %
Geode Capital Management, LLC2,46 %
Charles Schwab Investment Management, Inc.2,20 %
Morgan Stanley1,97 %
O firme (popis z Yahoo Finance, anglicky)
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou MRK.